[
  {
    "tag_no": "[1424]",
    "data": [
      "Table 23 description",
      "Experimental conditions"
    ],
    "summary_english": "Experimental conditions for preparing lipid compositions, referencing molar ratios in Table 23."
  },
  {
    "tag_no": "[1436]",
    "data": [
      "Table 1A description",
      "Table 1B description",
      "Experimental conditions"
    ],
    "summary_english": "Setup for initial studies comparing LNP delivery efficiency, referencing characteristics summarized in Tables 1A and 1B."
  },
  {
    "tag_no": "[1437]",
    "data": [
      "Table 1A",
      "Table 1B",
      "Experimental results"
    ],
    "summary_english": "Physicochemical characteristics including size, polydispersity, and encapsulation efficiency for various nanoparticle compounds shown in Tables 1A and 1B."
  },
  {
    "tag_no": "[1438]",
    "data": [
      "Table 1A description",
      "Table 2",
      "Experimental results"
    ],
    "summary_english": "Bioluminescence study results measuring luciferase expression (Total Flux) over 24 hours, detailed in Table 2."
  },
  {
    "tag_no": "[1439]",
    "data": [
      "Table 3A",
      "Table 3B",
      "Table 3C",
      "Table 3D",
      "Fig 8 description",
      "Experimental results"
    ],
    "summary_english": "Comparison of luciferase expression and lipid clearance relative to MC3 standard across multiple LNP formulations, with results in Tables 3A-D and Figure 8."
  },
  {
    "tag_no": "[1440]",
    "data": [
      "Table 1A description",
      "Table 4",
      "Experimental results"
    ],
    "summary_english": "Organ-specific (liver, lung, spleen, femur) luciferase expression data for sample formulations, detailed in Table 4."
  },
  {
    "tag_no": "[1441]",
    "data": [
      "Table 5A",
      "Experimental conditions",
      "Experimental results"
    ],
    "summary_english": "Total flux measured after intramuscular administration of nanoparticle compositions at different dose levels, shown in Table 5A."
  },
  {
    "tag_no": "[1442]",
    "data": [
      "Table 5B",
      "Experimental conditions",
      "Experimental results"
    ],
    "summary_english": "Luciferase expression data for additional intramuscularly administered compounds, detailed in Table 5B."
  },
  {
    "tag_no": "[1443]",
    "data": [
      "Table 6",
      "Experimental results"
    ],
    "summary_english": "Comparison of relative luciferase flux between intravenous and intramuscular administration routes in Table 6."
  },
  {
    "tag_no": "[1444]",
    "data": [
      "Table 1A description",
      "Table 7",
      "Experimental results"
    ],
    "summary_english": "Measurement of cytokine induction (IL-6 and IP-10) for selected compounds, shown in Table 7."
  },
  {
    "tag_no": "[1445]",
    "data": [
      "Table 1A description",
      "Table 8",
      "Experimental results"
    ],
    "summary_english": "Evaluation of complement activation levels (sC5b-9) for specific nanoparticle compositions, detailed in Table 8."
  },
  {
    "tag_no": "[1446]",
    "data": [
      "Table 9",
      "Experimental results"
    ],
    "summary_english": "Clinical markers including liver enzymes and white blood cell levels measured after intravenous administration, shown in Table 9."
  },
  {
    "tag_no": "[1447]",
    "data": [
      "Table 10",
      "Table 1B description",
      "Experimental conditions"
    ],
    "summary_english": "Characteristics of nanoparticle compositions formulated with hEPO mRNA, detailed in Table 10."
  },
  {
    "tag_no": "[1448]",
    "data": [
      "Table 11A",
      "Table 11B",
      "Table 1B description",
      "Fig 9 description",
      "Experimental results"
    ],
    "summary_english": "Comparison of hEPO expression and cytokine levels in mice across various LNP formulations and administration routes, shown in Tables 11A-B and referencing Figure 9."
  },
  {
    "tag_no": "[1449]",
    "data": [
      "Table 12",
      "Experimental results"
    ],
    "summary_english": "Direct performance comparison between novel compounds and the MC3 standard in Table 12."
  },
  {
    "tag_no": "[1451]",
    "data": [
      "Table 13",
      "Table 14",
      "Table 15",
      "Experimental results"
    ],
    "summary_english": "Evaluation of hEPO expression, cytokine induction, and residual lipid levels in the liver after 48 hours in rats, detailed in Tables 13, 14, and 15."
  },
  {
    "tag_no": "[1452]",
    "data": [
      "Table 16",
      "Table 17",
      "Table 18",
      "Experimental results"
    ],
    "summary_english": "Ratios of hEPO expression and lipid accumulation in liver and spleen tissues for rats across different dose levels, detailed in Tables 16, 17, and 18."
  },
  {
    "tag_no": "[1453]",
    "data": [
      "Table 19",
      "Experimental results"
    ],
    "summary_english": "Comprehensive assessment of expression, cytokine induction, lipid levels, and clinical chemistry in rats for Compounds 48-50, shown in Table 19."
  },
  {
    "tag_no": "[1454]",
    "data": [
      "Fig 3 description",
      "Fig 4 description",
      "Fig 5 description",
      "Fig 6 description",
      "Experimental results"
    ],
    "summary_english": "Analysis of dose-response for hEPO expression in rats, referencing data visualized in Figures 3 through 6."
  },
  {
    "tag_no": "[1455]",
    "data": [
      "Fig 7 description",
      "Experimental results"
    ],
    "summary_english": "Presentation of Area Under the Curve (AUC) data for various dosages, referencing Figure 7."
  },
  {
    "tag_no": "[1456]",
    "data": [
      "Table 20",
      "Table 21",
      "Table 22",
      "Experimental results"
    ],
    "summary_english": "Pharmacokinetic data including hEPO expression and lipid levels in the liver and spleen over 48 hours in rats, shown in Tables 20, 21, and 22."
  },
  {
    "tag_no": "[1467]",
    "data": [
      "Table 23"
    ],
    "summary_english": "List of exemplary nanoparticle formulations with varied molar ratios of components provided in Table 23."
  },
  {
    "tag_no": "[1470]",
    "data": [
      "Table 24",
      "Experimental conditions"
    ],
    "summary_english": "Study protocol for evaluating pretreatment effects with dexamethasone and acetaminophen, detailed in Table 24."
  },
  {
    "tag_no": "[1473]",
    "data": [
      "Table 25",
      "Experimental conditions"
    ],
    "summary_english": "Dosing protocol and pretreatment groups for non-human primate (NHP) studies using hEPO mRNA, detailed in Table 25."
  },
  {
    "tag_no": "[1474]",
    "data": [
      "Fig 1 description",
      "Experimental results"
    ],
    "summary_english": "Evaluation of pretreatment effectiveness on protein expression over time in primates, referencing Figure 1."
  },
  {
    "tag_no": "[1475]",
    "data": [
      "Table 26",
      "Table 27",
      "Table 28",
      "Table 29",
      "Experimental results"
    ],
    "summary_english": "Comprehensive NHP data including hEPO concentration, PK parameters, complement activation, and cytokine induction, detailed in Tables 26 through 29."
  },
  {
    "tag_no": "[1477]",
    "data": [
      "Table 30",
      "Table 31",
      "Experimental results"
    ],
    "summary_english": "Physical characteristics and comparative rodent/NHP expression efficiency for lead compounds, detailed in Tables 30 and 31."
  },
  {
    "tag_no": "[1478]",
    "data": [
      "Fig 2 description",
      "Experimental results"
    ],
    "summary_english": "Validation of hEPO expression levels in cynomolgus monkeys, referencing Figure 2."
  },
  {
    "tag_no": "[1479]",
    "data": [
      "Table 32",
      "Experimental results"
    ],
    "summary_english": "Pharmacokinetic parameters measured in primates comparing novel formulations to MC3 standard in Table 32."
  },
  {
    "tag_no": "[1480]",
    "data": [
      "Table 33",
      "Experimental results"
    ],
    "summary_english": "Characterization of LNPs containing anti-HA antibody mRNA, detailed in Table 33."
  },
  {
    "tag_no": "[1481]",
    "data": [
      "Table 34",
      "Fig 11 description",
      "Experimental results"
    ],
    "summary_english": "Anti-HA antibody expression levels and AUC comparison in Table 34 and referencing Figure 11."
  }
]